# Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.

- **DOI:** [10.1002/alz.71404](https://doi.org/10.1002/alz.71404)
- **Rating:** Strong (3.8 out of 5)
- **Verdict:** A focused synthesis maps anti-amyloid treatment decisions in Down syndrome, but its safety conclusions depend on indirect evidence.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-16
- **Evaluation page:** https://www.nabu.science/paper/10.1002%2Falz.71404

## Key claims

1. it seems likely that the side-effect risk from anti–amyloid-β monoclonal antibodies will be elevated in persons who have trisomy 21
   - Support: Tentative
   - Type: Primary finding
   - Basis: indirect neuropathological, imaging, and mechanistic evidence without DS-specific treatment safety outcomes
   - Location: Conclusions
2. These data suggest that younger persons with DS, particularly those under 30, may have a reduced risk of side effects from anti–amyloid-β monoclonal antibodies compared with older individuals.
   - Support: Tentative
   - Type: Secondary
   - Basis: age-related CAA observations rather than direct comparisons of treatment side effects
   - Location: The risk of amyloid-related imaging abnormalities and CAA in persons who have DS
3. APOE genotype and age are paramount safety considerations for the use of anti–amyloid-β antibodies in persons with DS.
   - Support: Tentative
   - Type: Secondary
   - Basis: mixed APOE–CAA findings and imaging associations without direct DS-specific antibody safety validation
   - Location: The risk of ARIA and blood pressure in persons who have DS

## Strengths

- **Integrates distinct biological and clinical considerations** The review connects CAA, blood–brain-barrier changes, immune biology, and antibody targeting to treatment-access and trial-design questions specific to Down syndrome.
  - Dimension: contribution
  - Location: Potential risks associated with anti-amyloid monoclonal antibodies for persons who have DS; Clinical trials for persons with DSAD
- **Engages evidence that complicates elevated risk** The discussion includes lower APOEε4 prevalence, mixed APOE–CAA associations, and similar Lecanemab binding in DSAD and late-onset AD tissue rather than treating all biological differences as evidence of greater harm.
  - Dimension: methodological rigour
  - Location: The risk of ARIA and APOE genotype in persons who have DS; The risk of ARIA and amyloid structure in persons who have DS
- **Connects uncertainty to concrete trial limitations** The ALADDIN discussion distinguishes amyloid-PET outcomes from clinical efficacy and identifies how its cognitive measure and eligibility criteria constrain applicability.
  - Dimension: positioning
  - Location: Clinical trials for persons with DSAD

## Limitations

- **Safety inference lacks direct treatment evidence** Elevated side-effect risk is inferred from neuropathology, imaging, and biological differences rather than observed antibody outcomes in people with Down syndrome. The conclusion is a hypothesis, not an established treatment-risk estimate.
  - Dimension: contribution
  - Location: Potential risks associated with anti-amyloid monoclonal antibodies for persons who have DS; Conclusions
- **Proposed safety window remains clinically unresolved** The suggestion that younger adults may have lower CAA-related risk is not reconciled with the drugs' early symptomatic indication and the later emergence of cognitive decline in DSAD.
  - Dimension: methodological rigour
  - Location: Anti–amyloid-β monoclonal antibody therapy for AD; The risk of amyloid-related imaging abnormalities and CAA in persons who have DS; Conclusions
- **Source selection remains dependent on judgment** Search sources and terms are reported, but selection rests on author-assessed relevance without formal inclusion criteria or source-quality assessment. The review does not explicitly examine how those choices constrain its synthesis.
  - Dimension: methodological rigour
  - Location: Methodology

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The blanket declaration of no competing interests sits alongside disclosure of paid consultancies; the substantive disclosure is present.
  - Conflict of interest: declared
- **Reference integrity:** Clean
  - 177 references in manuscript
  - 171 of 171 checkable references found in an index
  - 6 are books, websites or datasets — counted, but not index-checkable
  - 16 DOIs could not be checked:
    - #160 Jones JT , Talib N , Lovell D , Becker ML . Clinical features and treatment of Down syndrome arthropathy: experience from two US tertiary hospitals . Paediatr Drugs . 2019 ; 21 ( 1 ): 33 ‐ 39 . doi: 10.1007/s40272-018-0322-0 (beyond the 150 accuracy-lookup cap)
    - #161 Swanson CJ , Zhang Y , Dhadda S , et al. A randomized, double‐blind, phase 2b proof‐of‐concept clinical trial in early Alzheimer's disease with lecanemab, an anti‐Abeta protofibril antibody . Alzheimers Res Ther . 2021 ; 13 ( 1 ): 80 . doi: 10.1186/s13195-021-00813-8 (beyond the 150 accuracy-lookup cap)
    - #162 Fertan E , Lam JYL , Albertini G , et al. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease . Alzheimers Dement . 2025 ; 21 ( 4 ): e70086 . doi: 10.1002/alz.70086 (beyond the 150 accuracy-lookup cap)
    - #163 Fernandez A , Hoq MR , Hallinan GI , et al. Cryo‐EM structures of amyloid‐beta and tau filaments in Down syndrome . Nat Struct Mol Biol . 2024 ; 31 ( 6 ): 903 ‐ 909 . doi: 10.1038/s41594-024-01252-3 (beyond the 150 accuracy-lookup cap)
    - #164 Fertan E , Lam JYL , Albertini G , et al. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease . Alzheimers Dement . 2025 ; 21 ( 4 ): e70086 . doi: 10.1002/alz.70086 40237235 PMC12001052 (beyond the 150 accuracy-lookup cap)
    - #165 Fernandez A , Hoq MR , Hallinan GI , et al. Cryo‐EM structures of amyloid‐beta and tau filaments in Down syndrome . Nat Struct Mol Biol . 2024 ; 31 ( 6 ): 903 ‐ 909 . doi: 10.1038/s41594-024-01252-3 38553642 PMC11189299 (beyond the 150 accuracy-lookup cap)
    - #166 Maxwell AM , Yuan P , Rivera BM , et al. Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome . Acta Neuropathol Commun . 2021 ; 9 ( 1 ): 201 . doi: 10.1186/s40478-021-01298-0 34961556 PMC8711167 (beyond the 150 accuracy-lookup cap)
    - #167 Johannesson M , Sahlin C , Soderberg L , et al. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease . Mol Cell Neurosci . 2021 ; 114 : 103641 . doi: 10.1016/j.mcn.2021.103641 34091073 (beyond the 150 accuracy-lookup cap)
    - #168 Liu L , Saba A , Pascual JR , et al. Lecanemab and vascular‐amyloid deposition in brains of people with Down syndrome . JAMA Neurol . 2024 ; 81 ( 10 ): 1066 ‐ 1072 . doi: 10.1001/jamaneurol.2024.2579 39158850 PMC11334015 (beyond the 150 accuracy-lookup cap)
    - #169 Bayer TA . Pyroglutamate abeta cascade as drug target in Alzheimer's disease . Mol Psychiatry . 2022 ; 27 ( 4 ): 1880 ‐ 1885 . doi: 10.1038/s41380-021-01409-2 34880449 PMC9126800 (beyond the 150 accuracy-lookup cap)
    - #170 Bouter Y , Liekefeld H , Pichlo S , et al. Donanemab detects a minor fraction of amyloid‐beta plaques in post‐mortem brain tissue of patients with Alzheimer's disease and Down syndrome . Acta Neuropathol . 2022 ; 143 ( 5 ): 601 ‐ 603 . doi: 10.1007/s00401-022-02418-3 35429251 PMC9038931 (beyond the 150 accuracy-lookup cap)
    - #171 Rizvi B , Lao PJ , Sathishkumar M , et al. A pathway linking pulse pressure to dementia in adults with Down syndrome . Brain Commun . 2024 ; 6 ( 3 ): fcae157 . doi: 10.1093/braincomms/fcae157 38764776 PMC11099660 (beyond the 150 accuracy-lookup cap)
    - #172 Grimm HP , Schumacher V , Schafer M , et al. Delivery of the Brainshuttle amyloid‐beta antibody fusion trontinemab to non‐human primate brain and projected efficacious dose regimens in humans . MAbs . 2023 ; 15 ( 1 ): 2261509 . doi: 10.1080/19420862.2023.2261509 37823690 PMC10572082 (beyond the 150 accuracy-lookup cap)
    - #173 Muliaditan M , van Steeg TJ , Avery LB , et al. Translational minimal physiologically based pharmacokinetic model for transferrin receptor‐mediated brain delivery of antibodies . MAbs . 2025 ; 17 ( 1 ): 2515414 . doi: 10.1080/19420862.2025.2515414 40568753 PMC12203839 (beyond the 150 accuracy-lookup cap)
    - #175 Barroeta I , Videla L , Carmona‐Iragui M , Fortea J , Rafii MS . Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: navigating new therapeutic frontiers . Alzheimers Dement . 2025 ; 21 ( 6 ): e70258 . doi: 10.1002/alz.70258 40528298 10.1002/alz.70258 PMC12173829 (beyond the 150 accuracy-lookup cap)
    - #176 Vukicevic M , Fiorini E , Siegert S , et al. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: pyroglutamate amyloid beta . Brain Commun . 2022 ; 4 ( 1 ): fcac022 . doi: 10.1093/braincomms/fcac022 35479516 10.1093/braincomms/fcac022 PMC9037369 (beyond the 150 accuracy-lookup cap)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
